8-K Announcements
6Material company update
Nov 13, 2025·SEC
Material company update
Nov 10, 2025·SEC
Material company update
Nov 6, 2025·SEC
Metsera, Inc.(MTSR)Earnings, Financials & Key Ratios
MTSR•NASDAQ
Price updated Apr 24, 2026
AboutMetsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$225M-414.8%
- Net Income-$209M-343.0%
- EPS (Diluted)-2.03-113.7%
- ROE-108.4%-126.2%
MTSR Key Insights
Metsera, Inc. (MTSR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 92 (top 8%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 25.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MTSR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MTSR Price & Volume
Metsera, Inc. (MTSR) stock price & volume — 10-year historical chart
Loading chart...
MTSR Growth Metrics
Metsera, Inc. (MTSR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-56.92%
5 Years-56.92%
3 Years-56.92%
Last Year-84.47%
MTSR Recent Earnings
Metsera, Inc. (MTSR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/4 qtrs (0%)
Q4 2025Latest
Nov 12, 2025Metric
Actual
Est
EPS
$1.11-98.2%
$0.56
Rev
—
—
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$0.66-0.3%
$0.66
Rev
—
—
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$1.03-21.2%
$0.85
Rev
—
—
Q2 2025
Mar 26, 2025Metric
Actual
Est
EPS
$3.52-340.0%
$0.80
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $1.11vs $0.56-98.2% | — |
| Q3 2025 | Jul 28, 2025 | $0.66vs $0.66-0.3% | — |
| Q2 2025 | May 12, 2025 | $1.03vs $0.85-21.2% | — |
| Q2 2025 | Mar 26, 2025 | $3.52vs $0.80-340.0% | — |
Based on last 4 quarters of dataView full earnings history →
MTSR Peer Comparison
Metsera, Inc. (MTSR) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 GPCR | 2.56B | 44.51 | -18.55 | -15.14% | 0.00 | |||
 PEPG | 123.81M | 1.79 | -0.84 | -59.89% | 0.12 | |||
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 RYTM | 6.63B | 96.79 | -31.12 | 45.83% | -93.84% | -204.35% | 1.77 |
Compare MTSR vs Peers
Metsera, Inc. (MTSR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MTSR Income Statement
Metsera, Inc. (MTSR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 |
Revenue Growth % | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 |
COGS % of Revenue | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - |
Gross Profit Growth % | - | - | - |
Operating Expenses | 43.67M | 224.83M | 337.51M |
OpEx % of Revenue | - | - | - |
Selling, General & Admin | 15.04M | 26.8M | 44.86M |
SG&A % of Revenue | - | - | - |
Research & Development | 15.56M | 107.52M | 220.3M |
R&D % of Revenue | - | - | - |
Other Operating Expenses | 13.06M | 90.52M | 2.13M |
Operating Income | -43.67M▲ 0% | -224.83M▼ 414.9% | -337.51M▲ 0% |
Operating Margin % | - | - | - |
Operating Income Growth % | - | -414.86% | - |
EBITDA | -43.67M | -224.82M | -337.48M |
EBITDA Margin % | - | - | - |
EBITDA Growth % | - | -414.85% | - |
D&A (Non-Cash Add-back) | 2K | 14K | 35K |
EBIT | -47.21M | -218.24M | -393.97M |
Net Interest Income | 1.92M | 5.96M | 17.83M |
Interest Income | 1.92M | 6.18M | 17.98M |
Interest Expense | 0 | 223K | 152K |
Other Income/Expense | -3.54M | 6.37M | 14.71M |
Pretax Income | -47.21M▲ 0% | -218.47M▼ 362.8% | -322.81M▲ 0% |
Pretax Margin % | - | - | - |
Income Tax | 0 | -9.34M | -8.4M |
Effective Tax Rate % | 0% | 4.27% | 2.6% |
Net Income | -47.21M▲ 0% | -209.13M▼ 343.0% | -314.41M▲ 0% |
Net Margin % | - | - | - |
Net Income Growth % | - | -343.01% | - |
Net Income (Continuing) | -47.21M | -209.13M | -314.41M |
Discontinued Operations | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 |
EPS (Diluted) | -0.95▲ 0% | -2.03▼ 113.7% | -2.99▲ 0% |
EPS Growth % | - | -113.68% | - |
EPS (Basic) | -0.95 | -2.03 | - |
Diluted Shares Outstanding | 49.94M | 103.04M | 105.03M |
Basic Shares Outstanding | 49.94M | 103.04M | 105.03M |
Dividend Payout Ratio | - | - | - |
MTSR Balance Sheet
Metsera, Inc. (MTSR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
Total Current Assets | 76.8M | 359.13M | 461.41M |
Cash & Short-Term Investments | 75.19M | 352.45M | 448.46M |
Cash Only | 75.19M | 352.45M | 448.46M |
Short-Term Investments | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - |
Inventory | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - |
Other Current Assets | 761K | 4.63M | 2.29M |
Total Non-Current Assets | 92.04M | 91.86M | 106.23M |
Property, Plant & Equipment | 27K | 1.44M | 641K |
Fixed Asset Turnover | - | - | 0.00x |
Goodwill | 22.18M | 21.89M | 23.4M |
Intangible Assets | 69.42M | 68.52M | 73.25M |
Long-Term Investments | 0 | 0 | 0 |
Other Non-Current Assets | 410K | 0 | 8.94M |
Total Assets | 168.84M▲ 0% | 450.99M▲ 167.1% | 567.64M▲ 0% |
Asset Turnover | - | - | 0.00x |
Asset Growth % | - | 167.11% | 97.6% |
Total Current Liabilities | 20.17M | 67.31M | 108.49M |
Accounts Payable | 2.66M | 20.84M | 20.23M |
Days Payables Outstanding | - | - | - |
Short-Term Debt | 0 | 8.39M | 2.41M |
Deferred Revenue (Current) | 0 | 0 | 0 |
Other Current Liabilities | 14.86M | 25.32M | 56.59M |
Current Ratio | 3.81x | 5.34x | 4.25x |
Quick Ratio | 3.81x | 5.34x | 4.25x |
Cash Conversion Cycle | - | - | - |
Total Non-Current Liabilities | 50.17M | 96.33M | 121.96M |
Long-Term Debt | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 701K | 1.6M |
Deferred Tax Liabilities | 17.67M | 7.78M | 32.6M |
Other Non-Current Liabilities | 32.5M | 87.85M | 113.58M |
Total Liabilities | 70.34M | 163.64M | 230.45M |
Total Debt | 0 | 9.8M | 2.84M |
Net Debt | -75.19M | -342.64M | -445.62M |
Debt / Equity | - | 0.03x | 0.01x |
Debt / EBITDA | - | - | -0.01x |
Net Debt / EBITDA | - | - | 1.32x |
Interest Coverage | - | -1008.22x | -2591.91x |
Total Equity | 98.5M▲ 0% | 287.35M▲ 191.7% | 337.19M▲ 0% |
Equity Growth % | - | 191.72% | 159.8% |
Book Value per Share | 1.97 | 2.79 | 3.21 |
Total Shareholders' Equity | 98.5M | 287.35M | 337.19M |
Common Stock | 0 | 0 | 1K |
Retained Earnings | -48.02M | -257.15M | -518.68M |
Treasury Stock | 0 | 0 | 0 |
Accumulated OCI | 2.75M | 1.16M | 10.55M |
Minority Interest | 0 | 0 | 0 |
MTSR Cash Flow Statement
Metsera, Inc. (MTSR) cash flow — operating, investing & free cash flow history
| Metric | Dec'23 | Dec'24 | TTM |
|---|---|---|---|
Cash from Operations | -35.39M | -99.79M | -231.4M |
Operating CF Margin % | - | - | - |
Operating CF Growth % | - | -181.94% | -188.76% |
Net Income | -47.21M | -209.13M | -314.41M |
Depreciation & Amortization | 2K | 14K | 35K |
Stock-Based Compensation | 85K | 0 | 7.84M |
Deferred Taxes | 0 | -9.34M | 0 |
Other Non-Cash Items | 7.7M | 92.92M | 59.98M |
Working Capital Changes | 4.02M | 25.75M | 15.16M |
Change in Receivables | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 |
Change in Payables | 2.6M | 16.55M | 8.73M |
Cash from Investing | -28.24M | -43K | -199K |
Capital Expenditures | -29K | -43K | -199K |
CapEx % of Revenue | - | - | - |
Acquisitions | -28.21M | 0 | 0 |
Investments | - | - | - |
Other Investing | 0 | 0 | 0 |
Cash from Financing | 123.68M | 377.95M | 489.63M |
Debt Issued (Net) | 0 | -252K | -125K |
Equity Issued (Net) | 1000K | 1000K | 2.33M |
Dividends Paid | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 |
Other Financing | -217K | -18.98M | -14.11M |
Net Change in Cash | 60.22M▲ 0% | 277.25M▲ 360.4% | 260.87M▲ 0% |
Free Cash Flow | -35.42M▲ 0% | -99.83M▼ 181.8% | -231.59M▲ 0% |
FCF Margin % | - | - | - |
FCF Growth % | - | -181.83% | - |
FCF per Share | -0.71 | -0.97 | -2.21 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.48x | 0.74x |
Interest Paid | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 |
MTSR Key Ratios
Metsera, Inc. (MTSR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2024 | TTM |
|---|---|---|
Return on Equity (ROE) | -108.4% | -93.24% |
Return on Invested Capital (ROIC) | - | 318.84% |
Debt / Equity | 0.03x | 0.01x |
Interest Coverage | -1008.22x | -2591.91x |
FCF Conversion | 0.48x | 0.74x |
Related:MTSR Dividend History·MTSR Revenue History·MTSR Price History·MTSR P/E History·MTSR Financial Ratios·MTSR Institutional Holders
MTSR SEC Filings & Documents
Metsera, Inc. (MTSR) SEC filings — annual & quarterly reports (10-K, 10-Q)
MTSR Frequently Asked Questions
Metsera, Inc. (MTSR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Metsera, Inc. (MTSR) grew revenue by 0.0% over the past year. Growth has been modest.
Metsera, Inc. (MTSR) reported a net loss of $314.4M for fiscal year 2024.
Dividend & Returns
Metsera, Inc. (MTSR) has a return on equity (ROE) of -108.4%. Negative ROE indicates the company is unprofitable.
Metsera, Inc. (MTSR) had negative free cash flow of $231.6M in fiscal year 2024, likely due to heavy capital investments.